Smith Supports Goggles for Docs

Smith Supports Goggles for Docs

Friday, April 3 2020 | 11 h 42 min | News, Press Release

Safilo Group announces that its own Smith brand has joined Goggles for Docs, a movement to support local and national personal protective equipment (PPE) shortages across the US. Smith will provide ski goggles to healthcare workers who currently have no eyewear protection while treating patients in the wake of COVID-19.

The Goggles for Docs program materialized in just a few days to support hospital need, and is based solely on volunteer support and product donation. Smith is currently sending new and used goggles to fulfill hospital requests, and will continue to promote the program, encouraging its community to volunteer and donate on the individual level.

Click HERE for the full press release.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Smith Supports Goggles for Docs

Featured Posts